Cargando…

The Helicobacter pylori single nucleotide polymorphisms SNPs associated with multiple therapy resistance in Colombia

The eradication of Helicobacter pylori (H. pylori) using multiple therapies is used as a prevention strategy. However, its efficacy has been compromised by the emergence of single nucleotide polymorphisms in genes associated with H. pylori's resistance to multiple antibiotics. To estimate antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzman, Kevin, Montenegro, Lidia, Pazos, Alvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361749/
https://www.ncbi.nlm.nih.gov/pubmed/37485536
http://dx.doi.org/10.3389/fmicb.2023.1198325
_version_ 1785076277460336640
author Guzman, Kevin
Montenegro, Lidia
Pazos, Alvaro
author_facet Guzman, Kevin
Montenegro, Lidia
Pazos, Alvaro
author_sort Guzman, Kevin
collection PubMed
description The eradication of Helicobacter pylori (H. pylori) using multiple therapies is used as a prevention strategy. However, its efficacy has been compromised by the emergence of single nucleotide polymorphisms in genes associated with H. pylori's resistance to multiple antibiotics. To estimate antibiotic resistance rates associated with mutations in H. pylori genes in the high-cancer-risk population in Colombia, we included 166 H. pylori whole genome sequences from a cohort of individuals with a high risk of gastric cancer. By using the reference strain ATCC 26695, we identified mutations in specific genes to evaluate resistance rates for different antibiotics: 23S rRNA for clarithromycin, 16S rRNA for tetracycline, pbp1A for amoxicillin, gyrA for levofloxacin, and rdxA for metronidazole. The phylogenomic analysis was conducted using the core genome consisting of 1,594 genes of H. pylori-ATCC 26695. Our findings revealed that the resistance rate of H. pylori to clarithromycin was 3.62%, primarily associated with mutations A2143G and A2142G in the 23S rRNA gene. For tetracycline, the resistance rate was 7.23%, with mutations A926G, A926T, and A928C observed in the 16S rRNA gene. Amoxicillin resistance was found in 25.9% of cases, with observed mutations in the pbp1A gene, including T556S, T593, R649K, R656P, and R656H. In the gyrA gene, mutations N87K, N87I, D91G, D91N, and D91Y were identified, resulting in a resistance rate of 12.04% to levofloxacin. The most common mutations in the rdxA gene associated with metronidazole resistance were a stop codon, and mutations at D59N and D59S, resulting in a resistance rate of 99.3%. The high resistance rate of H. pylori to metronidazole indicated that this drug should be excluded from the eradication therapy. However, the resistance rates for tetracycline and clarithromycin did not exceed the established resistance threshold in Colombia. The increased resistance rate of H. pylori to levofloxacin and amoxicillin may partially explain the observed therapeutic failures in Colombia. The phylogenomic tree showed that the H. pylori isolate belongs to its own lineage (hspColombia). These findings offer valuable insights to enhance the characterization of treatment protocols for the specific H. pylori lineage (hspColombia) at the local level.
format Online
Article
Text
id pubmed-10361749
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103617492023-07-22 The Helicobacter pylori single nucleotide polymorphisms SNPs associated with multiple therapy resistance in Colombia Guzman, Kevin Montenegro, Lidia Pazos, Alvaro Front Microbiol Microbiology The eradication of Helicobacter pylori (H. pylori) using multiple therapies is used as a prevention strategy. However, its efficacy has been compromised by the emergence of single nucleotide polymorphisms in genes associated with H. pylori's resistance to multiple antibiotics. To estimate antibiotic resistance rates associated with mutations in H. pylori genes in the high-cancer-risk population in Colombia, we included 166 H. pylori whole genome sequences from a cohort of individuals with a high risk of gastric cancer. By using the reference strain ATCC 26695, we identified mutations in specific genes to evaluate resistance rates for different antibiotics: 23S rRNA for clarithromycin, 16S rRNA for tetracycline, pbp1A for amoxicillin, gyrA for levofloxacin, and rdxA for metronidazole. The phylogenomic analysis was conducted using the core genome consisting of 1,594 genes of H. pylori-ATCC 26695. Our findings revealed that the resistance rate of H. pylori to clarithromycin was 3.62%, primarily associated with mutations A2143G and A2142G in the 23S rRNA gene. For tetracycline, the resistance rate was 7.23%, with mutations A926G, A926T, and A928C observed in the 16S rRNA gene. Amoxicillin resistance was found in 25.9% of cases, with observed mutations in the pbp1A gene, including T556S, T593, R649K, R656P, and R656H. In the gyrA gene, mutations N87K, N87I, D91G, D91N, and D91Y were identified, resulting in a resistance rate of 12.04% to levofloxacin. The most common mutations in the rdxA gene associated with metronidazole resistance were a stop codon, and mutations at D59N and D59S, resulting in a resistance rate of 99.3%. The high resistance rate of H. pylori to metronidazole indicated that this drug should be excluded from the eradication therapy. However, the resistance rates for tetracycline and clarithromycin did not exceed the established resistance threshold in Colombia. The increased resistance rate of H. pylori to levofloxacin and amoxicillin may partially explain the observed therapeutic failures in Colombia. The phylogenomic tree showed that the H. pylori isolate belongs to its own lineage (hspColombia). These findings offer valuable insights to enhance the characterization of treatment protocols for the specific H. pylori lineage (hspColombia) at the local level. Frontiers Media S.A. 2023-07-07 /pmc/articles/PMC10361749/ /pubmed/37485536 http://dx.doi.org/10.3389/fmicb.2023.1198325 Text en Copyright © 2023 Guzman, Montenegro and Pazos. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Guzman, Kevin
Montenegro, Lidia
Pazos, Alvaro
The Helicobacter pylori single nucleotide polymorphisms SNPs associated with multiple therapy resistance in Colombia
title The Helicobacter pylori single nucleotide polymorphisms SNPs associated with multiple therapy resistance in Colombia
title_full The Helicobacter pylori single nucleotide polymorphisms SNPs associated with multiple therapy resistance in Colombia
title_fullStr The Helicobacter pylori single nucleotide polymorphisms SNPs associated with multiple therapy resistance in Colombia
title_full_unstemmed The Helicobacter pylori single nucleotide polymorphisms SNPs associated with multiple therapy resistance in Colombia
title_short The Helicobacter pylori single nucleotide polymorphisms SNPs associated with multiple therapy resistance in Colombia
title_sort helicobacter pylori single nucleotide polymorphisms snps associated with multiple therapy resistance in colombia
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361749/
https://www.ncbi.nlm.nih.gov/pubmed/37485536
http://dx.doi.org/10.3389/fmicb.2023.1198325
work_keys_str_mv AT guzmankevin thehelicobacterpylorisinglenucleotidepolymorphismssnpsassociatedwithmultipletherapyresistanceincolombia
AT montenegrolidia thehelicobacterpylorisinglenucleotidepolymorphismssnpsassociatedwithmultipletherapyresistanceincolombia
AT pazosalvaro thehelicobacterpylorisinglenucleotidepolymorphismssnpsassociatedwithmultipletherapyresistanceincolombia
AT guzmankevin helicobacterpylorisinglenucleotidepolymorphismssnpsassociatedwithmultipletherapyresistanceincolombia
AT montenegrolidia helicobacterpylorisinglenucleotidepolymorphismssnpsassociatedwithmultipletherapyresistanceincolombia
AT pazosalvaro helicobacterpylorisinglenucleotidepolymorphismssnpsassociatedwithmultipletherapyresistanceincolombia